Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Recruiting · Phase 3 · NCT05263206
Conditions: Pruritus
At a glance
- Research payments reported, 2025
- $309,166
- U.S. investigators named
- 11
- Sites paid
- 12
- Planned or actual enrollment
- 284
About the trial
- Sponsor
- Sanofi
- Tested
- Dupilumab (drug), Placebo (drug), Fexofenadine (loratadine if not available) (drug)
- Dates
- Started 2022-02-15; completion 2027-08-25
- Results posted
- Not yet
The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design was to be adapted based on the results of Study A. For both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (worst-itch numerical rating scale \[WI-NRS ≥7) will enter a 4-week run-in period and will be treated with a non-sedative antihistamine and an emollient (moisturizer). Participants with severe pruritu…
From ClinicalTrials.gov, last updated 2026-10-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $309,166 in research payments for this study in 2025 (69 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Brian D. Modena, M.D., MSC Allergy & Immunology · La Jolla, CA
- Brad H. Goodman, M. D. Allergy & Immunology · Savannah, GA
- Cindy E. Owen, M.D. Dermatology · Louisville, KY
- Alison Ehrlich, MD Dermatology · Chevy Chase, MD
- Shawn Kwatra, M.D. Dermatology · Baltimore, MD
- Michael Blankinship Dermatology · Fargo, ND
- Linda B. Ford, M.D. Allergy & Immunology · Bellevue, NE
- Mark Lebwohl Dermatology · New York, NY
- Patrick L. Shannon, M.D. Specialist · Boardman, OH
- John Ramey, MD Allergy & Immunology · North Charleston, SC
- Bartley J. Gill, M.D., PH.D. Internal Medicine · Sugar Land, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Brian D Modena Orso Health Inc $88,839
- The Indiana Clinical Trials Center $65,269
- Red River Research PArtners Llc $34,103
- Complete Dermatology PLLC $29,112
- Aeroallergy Research Laboratories of Savannah Inc $27,682
- Natl Allergy Asthma Research Llc $21,048
- Probity Medical Research Corp $14,359
- Columbia Dermatology $13,600
- Nebraska Medical Research Inst Inc $7,206
- Scott Health Services Llc Ds Research $3,680
- Johns Hopkins University $2,568
- Mount Sinai School of Medicine Psychiatry $1,700
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.